(Q33682511)

28 July 2017

title

Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome (English)

1 reference

28 July 2017

1 reference

Malla AK

1

1 reference

28 July 2017

Norman RM

series ordinal

2

1 reference

28 July 2017

Kotteda V

series ordinal

3

1 reference

28 July 2017

Zirul S

series ordinal

4

1 reference

28 July 2017

publication date

1 May 1999

1 reference

28 July 2017

published in

Clinical Therapeutics

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

806-817

1 reference

The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Clozapine Study Group

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

An integrated medical and psychosocial treatment program for psychotic disorders: patient characteristics and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

IRAOS: an instrument for the assessment of onset and early course of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

Three syndrome concept of schizophrenia. A factor analytic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

New pharmacotherapeutic modalities for negative symptoms in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980003-4

7 January 2021

10.1016/S0149-2918(99)80003-4

Identifiers

DOI

1 reference

28 July 2017

1 reference